logo
  

Rite Aid February Same Store Sales Rise 3.3%

Retail drugstore chain operator Rite Aid Corp. (RAD) reported Friday a 3.3 percent increase in February same store sales, reflecting an improvement in pharmacy same store sales and front-end same store sales.

Camp Hill, Pennsylvania-based Rite Aid reported total drugstore sales of $2.56 billion for the month of February, up 1.7 percent from $2.51 billion in the comparable month a year ago.

Same store sales for the month of February improved 3.3 percent, reflecting a 4.1 percent increase in pharmacy same store sales, which included a 144 basis points negative impact of new generic introductions.

Front-end same store sales for the month also grew 1.6 percent, and prescription count at comparable stores increased 2.2 percent.

The company noted that prescription sales accounted for 69.2 percent of drugstore sales, and third party prescription revenue represented 97.6 percent of pharmacy sales.

For the fourth quarter, same store sales improved 4.5 percent, with front-end same store sales up 2.0 percent, and pharmacy same store sales increasing 5.7 percent.

Total drugstores sales for the quarter grew 3.5 percent to $6.80 billion from $6.56 billion in the prior-year quarter.

For the full-year-2014, same store sales improved 4.3 percent, with front-end same store sales edging up 1.2 percent, and pharmacy same store sales increasing 5.8 percent.

Total drugstores sales for the year grew 3.7 percent to $26.35 billion from $25.41 billion in the prior-year period.

In Thursday's regular trading session, RAD is currently trading at $7.93, down $0.12 or 1.49% on a volume of 1.50 million shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT